

List of Publications

Tim Heise, MD

Original papers

1. Heinemann L, Heise T, Kamper K.
Biotrans: description of a data transfer program for the Biostator.
International Journal of Artificial Organs 16:213-217, 1993
2. Heinemann L, Heise T, Nellesmann-Jørgensen L, Starke AAR.
Action profile of the rapid acting insulin analogue B28Asp.
Diabetic Medicine 10:535-539, 1993
3. Ampudia-Blasco FJ, Heinemann L, Bender R, Schmidt A, Heise T, Berger M, Starke AAR.
Comparative dose-related time-action profiles of glibenclamide and a new non-sulfonylurea drug, AG-EE 623 ZW, during euglycemic clamp in healthy subjects.
Diabetologia 37:703-707, 1994
4. Heinemann L, Heise T, Ampudia J, Heise T, Sawicki P, Sindelka G, Berger M, Starke AAR.
Four week administration of an ACE-inhibitor and a cardio-selective β -blocker in healthy volunteers: no influence on insulin sensitivity.
European Journal of Clinical Investigation 25:595-600, 1995
5. Heise T, Heinemann L, Richter B, Berger M, Sawicki PT.
Kosten von Medikamenten ohne gesicherte Wirkung in der Diabetestherapie.
Deutsches Ärzteblatt 92:A-3549-3554, 1995
6. Heinemann L, Heise T, Ampudia J, Klepper A, Bender R, Starke AAR.
Time action profiles of the intermediate-acting insulin analogue: des (64,65)-human proinsulin.
Diabète & Métabolisme 21:415-419, 1995
7. Richter B, Heise T, Berger M.
Dexfenfluramin-Neurotoxizität. (Letter)
Arzneimittelbrief 29:16, 1995
8. Heinemann L, Heise T, Wahl Ch, Trautmann ME, Ampudia J, Starke AAR, Berger M.
Prandial glycaemia after Pizza, Coke and Tiramisu in type I diabetic patients using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
Diabetic Medicine 13:625-629, 1996
9. Heinemann L, Kapitza C, Starke AAR, Heise T.
Time-action profile of the insulin analogue B28Asp. (Letter)
Diabetic Medicine 13:683-684, 1996
10. Heinemann L, Breuer J, Cebulla D, Wüssel B, Bender R, Heise T.
Wirkungsprofile von Normalinsulin, NPH-Insulin sowie einer 25/75-Mischung hergestellt aus gentechnologischem bzw. semisynthetischem Humaninsulin.
Diabetes und Stoffwechsel 5:157-163, 1996

11. Heinemann L, Traut T, Heise T.
Time-action profile of inhaled insulin.
Diabetic Medicine 14:63-72, 1997
12. Heinemann L, Weyer Ch, Rave K, Stiefelhagen O, Rauhaus M, Heise T.
Comparison of the time action profile of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28Asp.
Experimental and Clinical Endocrinology & Diabetes 105:131-135, 1997
13. Weyer C, Heise T, Heinemann L.
Insulin aspart in a 30/70 premixed formulation: pharmacodynamic properties of a rapid-acting insulin analogue in stable mixtures.
Diabetes Care 20:1612-1614, 1997
14. Weyer C, Gudat U, Heise T, Kimmerle R, Santen R, Schlaghecke R, Spraul M, Berger M.
Integrity of the hypothalamo-pituitary-adrenal axis in morbid human obesity.
Endocrinology and Metabolism 4:397-401, 1997
15. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, Woodworth J, Gudat U, Heinemann L.
Time-action profiles of novel premixed preparations of insulin lispro and NPL-insulin.
Diabetes Care 21:800-803, 1998
16. Heinemann L, Schmelzeisen-Redeker G on behalf of the Non-invasive task force.
Perspectives in diabetes therapy: non-invasive continuous glucose monitoring in type I diabetic patients.
Diabetologia 41:848-854, 1998
17. Heise T, Magnusson K, Heinemann L, Sawicki PT.
Effect of insulin on blood pressure in essential hypertension.
Hypertension 32:243-248, 1998
18. Heise T, Heinemann L, Starke AAR.
Simulated post aggression metabolism in healthy volunteers: metabolic changes and insulin resistance.
Metabolism 47:1263-1268, 1998
19. Rave K, Heise T, Weyer C, Herrnberger C, Bender R, Hirschberger S, Heinemann L.
Intramuscular vs. subcutaneous injection of regular insulin and insulin lispro: Comparison of the metabolic effects in healthy subjects.
Diabetic Medicine 15:747-751, 1998
20. Meinhold J, Heise T, Rave K, Heinemann L.
Electrocardiographic changes during insulin-induced hypoglycaemia in healthy subjects.
Hormone Metabolic Research 11:694-697, 1998
21. Weyer C, Linkeschowa R, Heise T, Giesen HT, Spraul M.
Implications of the traditional and the new ACSM physical activity recommendations on weight reduction in dietary treated obese subjects.
International Journal of Obesity 22:1071-1078, 1998

22. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T.
Variability of the metabolic effect of soluble insulin and the rapid acting insulin analogue insulin aspart.
Diabetes Care 21:1910-1914, 1998
23. Heise T, Magnusson K, Heinemann L, Sawicki PT.
Insulin resistance and the effect of insulin on blood pressure in essential hypertension.
Hypertension 32:243-248, 1998
24. Kimmerle R, Heinemann L, Heise T, Weyer Ch, Hirschberger S, Berger M.
Influence of continuous oestrogen-progestogen replacement therapy with estradiol-norethisterone preparations on insulin sensitivity in postmenopausal non-diabetic women.
Menopause 6:36-42, 1999
25. Rave K, Heinemann L, Puhl L, Gudat U, Woodworth J, Weyer C, Heise T.
Premixed formulations of insulin lispro: activity profiles in type 1 diabetic patients.
Diabetes Care 22:865-866, 1999
26. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T.
Time-action profile of the soluble, fatty acid acylated long-acting insulin analogue NN304.
Diabetic Medicine 16:332-338, 1999
27. Rave K, Heise T, Weyer C, Sawicki PT, Heinemann L.
Measurement of insulin sensitivity: influence of potassium supply during euglycaemic glucose clamps in healthy volunteers.
Experimental and Clinical Endocrinology & Diabetes 107:313-317, 1999
28. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT.
No influence of enalapril and nitrendipine on insulin sensitivity in patients with essential hypertension.
Hormone Metabolic Research 31:418-423, 1999
29. Rave K, Heinemann L, Puhl L, Gudat U, Woodworth JR, Weyer C, Heise T.
Premixed formulations of insulin Lispro. Activity profiles in type 1 diabetic patients (letter).
Diabetes Care 22:865-866, 1999
30. Rave K, Bender R, Heise T, Sawicki PT.
Value of blood pressure self-monitoring as a predictor of progression of diabetic nephropathy.
Journal of Hypertension 17:597-601, 1999
31. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT.
Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril.
Hormone Metabolic Research 31:418-423, 1999
32. Rave K, Heise T, Clausson P, Hirschberger S, Heinemann L.
Lack of effects of the beta3-adrenoreceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in Type 2 diabetic patients.
Experimental and Clinical Endocrinology & Diabetes 107:442-446, 1999

33. Heinemann L, Linkeschowa R, Rave K, Hompesch B, Sedlak M, Heise T.
Time-action profiles of the long-acting insulin analogue insulin glargine (HOE901) in comparison to NPH-insulin and placebo.
Diabetes Care 23:644-649, 2000
34. Heinemann L, Krämer U, Klötzer HM, Hein M, Hermann M, Rave K, Heise T for the Non-Invasive Task Force.
Non-invasive glucose measurement by monitoring of scattering coefficient during oral glucose tolerance tests.
Diabetes Technology & Therapeutics 2:211-220, 2000
35. Heinemann L, Klappoth W, Rave K, Hompesch B., Linkeschowa R, Heise T.
Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
Diabetes Care 23:1343-1347, 2000
36. Heise T, Magnusson K, Gröbel B, Heinemann L, Rave K, Bender R, Sawicki P.
How to measure blood pressure in patients with diabetic nephropathy? A cross-sectional evaluation of different methods and devices.
Blood Pressure Monitoring 5:175-180, 2000
37. Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT.
Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients.
Diabetes Care 24:886-890, 2001
38. Heise T, Jennen E, Hochlenert D, Weyer C, Sawicki PT.
Optimierung der Bluthochdruckbehandlung bei Diabetes mellitus. Ergebnisse des strukturierten Hypertonie-Behandlungs- und Schulungs-Programms.
Nieren- und Hochdruckkrankheiten 30:448-59, 2001
39. Heise T, Bott S, Rave K, Dressler A, Roskamp R, Heinemann L.
No evidence for accumulation of insulin glargine (Lantus[®]): a multiple injection study in patients with Type 1 diabetes.
Diabetic Medicine 19:490-495, 2002
40. Perera AD, Kapitza C, Nosek L, Fishman RS, Shapiro DA, Heise T, Heinemann L.
Intra-patient variability of the absorption and metabolic effect of insulin inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.
Diabetes Care 25:2276-2281, 2002
41. Heise T, Jennen E, Hochlenert D, Weyer C, Sawicki PT.
Wege zur Verbesserung der Qualität der antihypertensiven Therapie bei Diabetes mellitus – Ergebnisse des strukturierten Hypertonie Behandlungs- und Schulungsprogrammes.
Zeitschrift für Gastroenterologie 40 (Suppl 1):27-32, 2002
42. Heise T, Sawicki PT.
Does insulin preserve beta-cell function in type 2 diabetes?
Journal of Internal Medicine. 251:283-285, 2002
43. Heise T, Bott S, Rave K, Dressler A, Roskamp R, Heinemann L.
No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes.
Diabetic Medicine 19:490-495, 2002

44. Heise T, Koschinsky T, Heinemann L, Lodwig V, Glucose Monitoring Study Group. Hypoglycemia warning signal and glucose sensors: requirements and concepts. *Diabetes Technology & Therapeutics* 5:563-571, 2003
45. Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. *Diabetic Medicine* 21:500-501, 2004
46. Kapitza C, Hompesch M, Scharling B, Heise T. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. *Diabetes Technology & Therapeutics* 6:466-472, 2004
47. Kapitza C, Heise T, Fishman RS, Shapiro DA, Gopalakrishnan V, Rave K, Bott S, Perera AD, Heinemann L. Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. *Diabetes Technology & Therapeutics* 6:119-128, 2004
48. Heise T, Heinemann L, Heller S, Weyer C, Shen L, Strobel S, Kolterman O, Maggs D. Effect of pramlintide on symptom, catecholamine, and glucagon responses in healthy subjects. *Metabolism* 53:1227-1232, 2004
49. Heise T, Nosek L, Stender A, Biilmann Rønn B, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin Glargine in people with type 1 diabetes. *Diabetes* 53:1614-1620, 2004
50. Bott S, Tusek C, Heinemann L, Friberg HH, Heise T. The Pharmacokinetic and Pharmacodynamic Properties of Biphasic Insulin Aspart 70 (BIAsp 70) are Significantly Different from those of Biphasic Insulin Aspart 30 (BIAsp 30). *Experimental and Clinical Endocrinology & Diabetes* 113:545-50, 2005
51. Heise T, Bott S, Tusek C, Stephan JA, Kawabata T, Finco-Kent D, Liu C, Krasner A. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. *Diabetes Care* 28:2161-9, 2005
52. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin Glulisine in children and adolescents with type 1 diabetes. *Diabetes Care* 28:2100-5, 2005
53. Bott S, Shafagoj YA, Sawicki PT, Heise T. Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. *Hormone Metabolic Research* 37:445-9, 2005
54. Rave K, Flesch S, Kuhn-Velten WN, Hompesch BC, Heinemann L, Heise T. Enhancement of blood glucose lowering effect of a sulfonylurea when co-administered with an ACE inhibitor: results of a glucose-clamp study. *Diabetes/Metabolism Research and Reviews* 21:459-64, 2005

55. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T.
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.
Diabetes Care 28:1077-82, 2005
56. Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T.
Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Diabetic Medicine 23:522-528, 2006
57. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT.
Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients.
Journal of Hypertens 24:1397-1403, 2006
58. Hausmann M, Dellweg S, Osborn C, Heinemann L, Buchwald A, Rosskamp R, Genova P, Heise T.
Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Diabetes, Obesity and Metabolism 8:574-580, 2006
59. Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ.
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study.
Nephrology Dialysis Transplantation 21:2166-2171, 2006
60. Hompesch M, Troupin B, Heise T, Elbroend B, Endahl L, Haahr H, Heinemann L.
Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups.
Diabetes, Obesity and Metabolism 8:568-573, 2006
61. Klein O, Lyng J, Endahl J, Damholt B, Nosek L, Heise T.
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Diabetes, Obesity and Metabolism 9:290-299, 2007
62. Heise T, Pieber TR.
Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
Diabetes, Obesity and Metabolism 9:648-659, 2007
63. Heise T, Nosek L, Spitzer H, Heinemann L, Niemöller E, Frick AD, Becker RH.
Insulin glulisine: a faster onset of action compared with insulin lispro.
Diabetes, Obesity and Metabolism 9:746-53, 2007
64. Rave K, Heise T, Pfützner A, Boss AH.
Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes.
Diabetes Care 30:2307-8, 2007
65. Rave K, Roggen K, Dellweg S, Heise T, Tom Dieck, H.
Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting blood glucose.
British Journal of Nutrition 98:929-36, 2007

66. Rave K, Heise T, Heinemann L, Boss AH.
Inhaled Technosphere[®] Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes.
Journal of Diabetes Science and Technology 2:205-212, 2008
67. Heise T.
Clinical therapeutics. Realising the value of modern insulins: reaching further with rapid-acting insulin analogues.
XIX World Diabetes Congress, Cape Town, South Africa, December 3, 2006. Forward.
Clinical Therapeutics, 29 (Suppl D):S133-4, 2007
68. Heise T.
Getting Closer to Physiologic Insulin Secretion.
Clinical Therapeutics, 29 (Suppl D):S161, 2007
69. Becker RH, Frick AD, Teichert L, Nosek L, Heinemann L, Heise T, Rave K.
Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.
Diabetes, Obesity and Metabolism 10:1105-1113, 2008
70. Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.
The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
Diabetes Technology & Therapeutics 10:479-485, 2008
71. Heinemann L, Scheuch G, Heise T.
Inhaled Insulin: Take a Deep Breath, but How?
Journal of Diabetes Science and Technology 2:297-299, 2008
72. Krones R, Schütte C, Heise T.
The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes.
Diabetes, Obesity and Metabolism 11:41-44, 2009
73. Heise T, Heinemann L, Hövelmann U, Brauns B, Nosek L, Haahr HL, Olsen KJ.
Brief Report - Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human insulin and basal-bolus therapy.
Diabetes Care 32:1431-1433, 2009
74. Heise T, Brugger A, Cook C, Eckers U, Hutchcraft A, Nosek L, Rave K, Troeger J, Valaitis P, White S, Heinemann L.
PROMAXX[®] inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler.
Diabetes, Obesity and Metabolism 11:455-459, 2009
75. Schliess F, Heise T.
Insulin glulisine: preclinical hallmarks and clinical efficacy.
Therapy 6(2); 209-229, 2009
76. Heise T, Gräfe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA.
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Diabetes, Obesity and Metabolism 11:786-794, 2009

77. Arutchelvam V, Heise T, Dellweg S, Elbroend N, Minns I, Home PD.
Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
Diabetic Medicine 26:1027-1032, 2009
78. Kempf K, Martin S, Heise T.
Blutzuckermessgeräte zum Eigengebrauch. Möglichkeiten und Fehlerquellen bei der Selbstmessung.
Info Diabetologie 3:38-41, 2009
79. Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R.
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.
Diabetic Medicine 26:1156-1164, 2009
80. Heise T, Mathieu C, Hey-Hadavi J, Strack T, Lawrence D.
Glycemic Control with Preprandial Versus Basal Insulin in Patients with Type 2 Diabetes Mellitus Poorly Controlled by Oral Antidiabetes Agents
Diabetes Technology & Therapeutics 12, 135-141, 2010
81. Kapitza C, Zijlstra ED, Heinemann L, Castelli MC, Riley G, Heise T.
Oral Insulin: A comparison with Subcutaneous Regular Human Insulin in Type 2 Diabetic Patients.
Diabetes Care 33:1288-90, 2010
82. Arnolds S, Rave K, Hövelmann U, Fischer A, Sert-Langeron C, Heise T.
Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers.
Experimental and Clinical Endocrinology & Diabetes 118(9):662-4, 2010
83. Kempf K, Martin S, Heise T.
Blutzuckermessgeräte für Patienten.
Der Hausarzt 12:34-37, 2010
84. Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A.
Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide.
Journal of Clinical Pharmacology, July 29:doi:10.1177/0091270010374474, 2010
85. Arnolds S, Kuglin B, Kapitza C, Heise T.
How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
International Journal of Clinical Practice 64(10): 1415–1424, 2010.
86. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R.
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study.
Journal of Clinical Endocrinology & Metabolism, 95(11):5028-36, 2010.

Editorials, Review articles, Textbook Chapters, Letters

1. Heinemann L, Heise T, Ampudia J, Starke AAR.
Action profiles of rapid-acting human insulin analogues.
in: Berger M, Gries FA: *Frontiers in Insulin Pharmacology*.
Georg Thieme Verlag, Stuttgart, pp. 87-96, 1993
2. Heise T, Sawicki PT, Heinemann L.
Metabolische Begleitwirkungen von Antihypertensiva.
Fortschritte der Medizin, Behandlung der arteriellen Hypertonie im Alter,
Standortbestimmung 1993, Workshop vom 26.-27.11.1993 in Berlin, Urban & Vogel
Verlag, München, 1994, pp. 60-75
3. Heinemann L, Heise T, Ampudia-Blasco FJ, Sawicki P.
Einfluss von ACE-Hemmern auf die Insulinsensitivität: eine kritische Übersicht.
Nieren- und Hochdruckkrankheiten 24:240-245, 1995
4. Berger M, Sawicki PT, Heise T, Bucher E, Heinemann L, Richter B.
Kosten von Medikamenten ohne gesicherte Wirkung in der Diabetestherapie.
Krankenversicherung 48:63-67, 1996
5. Sawicki PT, Heise T, Berger M.
Antihypertensive treatment and mortality in diabetic patients. What is the evidence?
Diabetologia 40 (Suppl 2):S134-S137, 1997
6. Heise T, Berger M, Sawicki PT.
Non-evidence based concepts are still established in the treatment of IDDM.
Hormone Research 50 (Suppl 1):74-78, 1998
7. Heise T, Rave K, Weyer C, Heinemann L.
Measurement of insulin sensitivity with the euglycaemic clamp technique:
Methodological pitfalls.
International Journal of Diabetes & Metabolism 6:70-75, 1998
8. Heise T, Sawicki PT, Yudkin JS.
Report on the meetings of the Hypertension in Diabetes EASD Study Group (HID) in
1998.
Diabetologia 41:62-63 (EASD News section), 1998
9. Heinemann L, Heise T.
Neue Insuline. Kongressbericht vom ADA 1999.
Diabetes und Stoffwechsel 8:227-229, 1999
10. Sawicki PT, Heise T, Rave K.
Die Behandlung von Diabetikern mit Komplikationen.
In: Berger M (ed.): *Diabetes mellitus*, Urban & Fischer, München-Jena, 2000, 2nd
edition
11. Heise T, Sawicki PT.
Does insulin preserve β -cell function in type 2 diabetes? Editorial
Journal of Internal Medicine 251:283-285, 2002
12. Heinemann L, Heise T.
Insulin: What's new? (Kongressbericht vom EASD 2000)
Diabetes & Stoffwechsel 9:355-57, 2000.

13. Heinemann L, Kramer U, Klotzer HM, Hein M, Volz D, Hermann M, Heise T, Rave K for the Non-Invasive Task Force.
Noninvasive glucose measurement by monitoring of scattering coefficient during oral glucose tolerance tests.
Diabetes Technology & Therapeutics 2:211-220, 2000
14. Heise T, Heinemann L.
Rapid and long-acting analogues as an approach to improve insulin therapy: An evidence-based medicine assessment.
Current Pharmaceutical Design 7:1303-1325,2001
15. Heinemann L, Pfützner A, Heise T.
Alternative Routes of Administration as an Approach to Improved Insulin Therapy: Update on Dermal, Oral, Nasal and Pulmonary Insulin Delivery.
Current Pharmaceutical Design 7:1327-1351, 2001
16. Heinemann L, Heise T.
Klinische Wirkungen und Pharmakodynamik der Insulinanaloga Lispro, Aspart und Glargin.
Deutsche Medizinische Wochenschrift 126:597-604, 2001
17. Heinemann L, Pfützner A, Heise T.
Insulin inhalieren statt spritzen? Inhalatives Insulin als alternative Insulinapplikationsform.
Diabetes und Stoffwechsel 10:255-269, 2001
18. Heise T, Jennen E, Sawicki PT.
Optimierte Hypertonie-Therapie.
Zeitschrift für Ärztliche Fortbildung und Qualitätssicherung 95:349-355, 2001
19. Heise T, Jennen E, Hochlenert D, Weyer C, Sawicki PT.
Wege zur Verbesserung der Qualität der antihypertensiven Therapie bei Diabetes mellitus – Ergebnisse des strukturierten Hypertonie Behandlungs- und Schulungsprogrammes.
Zeitschrift für Gastroenterologie 40 (Suppl 1):S27-S32, 2002
20. Heise T, Heinemann L, Weyer C.
Amylin-Substitution mit Pramlintide als Ergänzung zur Insulintherapie: Ein physiologischer Ansatz zur Verbesserung der Stoffwechselkontrolle beim Typ-1 und Typ-2 Diabetes.
Diabetes und Stoffwechsel 11:233-244, 2002
21. Heise T, Koschinsky T, Heinemann L, Lodwig L on behalf of the Glucose Monitoring Study Group.
Hypoglycemia warning signal: Requirements and concepts.
Diabetes Technology & Therapeutics 5:563-572, 2003
22. Kapitza C, Heise T.
Therapiemöglichkeiten mit GLP-1 Analoga und Inkretinmimetika.
In: Gallwitz B (ed.): GLP 1 – Therapiepotential bei Diabetes mellitus, Uni-Med Verlag AG, Bremen-London-München, pp. 64-73, 2004
23. Demuth HC, Kapitza C, Heise T.
Typ 2 Diabetes – Therapie mittels DPP-IV-Inhibitoren.
In: Gallwitz B (ed.): GLP 1 – Therapiepotential bei Diabetes mellitus, Uni-Med Verlag AG, Bremen-London-München, pp. 76-89, 2004

24. Heinemann L, Heise T.
Current Status of the Development of Inhaled Insulin.
British Journal of Diabetes and Vascular Disease 4:295-301, 2004
25. Heise T, Kapitza C, Hompesch M, Heinemann L.
Inhaled Insulin as alternative delivers system for subjects with diabetes - A literature review.
Avances en Diabetologia 21:91-102, 2005
26. Arnolds S, Heise T.
Neue Formen der Insulinapplikation.
Der Diabetologe 2:332-339, 2006
27. Heise T.
Inhalatives Insulin.
In: Scherbaum WA (ed.): Pschyrembel Diabetologie, Walter de Gruyter, Berlin-New York, 2. Auflage, pp. 136-137, 2006
28. Arnolds S, Kapitza C, Heise T.
Therapiemöglichkeiten mit Inkretin-Mimetika und GLP-1-Analoga.
In: Gallwitz B (ed.): GLP 1 als Therapieprinzip bei Typ 2 Diabetes: Inkretin-Mimetika und DPP-4 Inhibitoren, Uni-Med Verlag AG, 2. Auflage, Bremen-London-München, pp. 74-86, 2006
29. Heise T, Bott S, Tusek C, Stephan J, Kawabata T, Finco-Kent D, Liu C, Krasner A.
The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin.
Diabetes Care 29:477-478, 2006
30. Arnolds S, Heise T.
Inhaled insulin.
Best Practice & Research Clinical Endocrinology & Metabolism 21:555-571, 2007
31. Heise T.
Was insulin review biased, or simply a victim of bad timing?
Journal of Family Practice 56:E1-4, 2007

Abstracts

1. Heise T, Heinemann L, Starke AAR.
Evaluation eines Modells für den Post-Aggressionsstoffwechsel.
Intensivmedizin und Notfallmedizin 28:307, 1991
2. Starke A, Heise T, Heinemann L.
Simulation der diabetogenen Stoffwechsellage im Post-Aggressions-Stoffwechsel.
Diabetes und Stoffwechsel 1:178, 1992
3. Heise T, Heinemann L, Jorgensen LN, Berger M, Starke AAR.
Wirkungsprofil des rasch wirkenden Insulin-Analogs: Humaninsulin B28Asp
Diabetes und Stoffwechsel 1:119, 1992
4. Heinemann L, Heise T, Starke AAR, Jorgensen LN, Berger M.
Action profile of the rapid acting insulin analogue, human insulin B28Asp.
Diabetes 41 (Suppl 1):192A, 1992
5. Heinemann L, Heise T, Starke AAR, Jorgensen LN, Berger M.
Action profile of the rapid acting insulin analogue, human insulin B28Asp.
Diabetologia 35 (Suppl 1):A3, 1992
6. Heise T, Kamper K, Heinemann L.
Practical evaluation of a data transfer program for the biostator
Journal of Artificial Organs 15:524, 1992
7. Heinemann L, Ampudia Blasco J, Heise T, Klepper A, Bender R, Attanasio A, Starke AAR.
Action profile of the intermediate acting des(64,65) human proinsulin analogue.
Experimental and Clinical Endocrinology & Diabetes 101 (Suppl 2):370-371, 1993
8. Heinemann L, Ampudia J, Klepper A, Bender R, Heise T, Starke AAR.
Des(64,65)-Proinsulin-Analagon: Dosisabhängigkeit des Wirkungsprofils dieses mittellang wirkenden Insulin-Agonisten.
Diabetes und Stoffwechsel 2 (Suppl 2):137, 1993
9. Ampudia Blasco J, Heinemann L, Schmidt A, Bender R, Heise T, Starke AAR.
Pharmakodynamische Eigenschaften von Sulfonylharnstoffen: Eine Untersuchung im euglykämischen Glucose-Clamp.
Diabetes und Stoffwechsel 2 (Suppl 2):107, 1993
10. Starke AAR, Heinemann L, Ampudia J, Heise T, Sawicki P, Sindelka G, Berger M.
Keine Beeinflussung der Insulinsensitivität durch ACE-Hemmer oder kardioselektive Beta-Blocker.
Diabetes und Stoffwechsel 2 (Suppl 2):194, 1993
11. Heinemann L, Ampudia Blasco J, Schmidt A, Bender R, Heise T, Starke AAR.
A new approach to study the pharmacodynamic properties of oral hypoglycemic agents.
Diabetes 42 (Suppl 1):207A, 1993
12. Ampudia Blasco J, Heinemann L, Schmidt A, Bender R, Heise T, Starke AAR.
Pharmacodynamic properties of sulfonylureas: a euglycaemic glucose-clamp study.
Diabetologia 36 (Suppl 1):A180, 1993

13. Heise T, Heinemann L, Ampudia J, Klepper A, Bender R, Starke AAR.
Des(64,65)-Proinsulin-Analagon: Dose-dependency of the time action profile of an intermediate acting insulin agonist.
Diabetologia 36 (Suppl 1):A155, 1993
14. Starke AAR, Heinemann L, Ampudia J, Heise T, Sawicki P, Sindelka G, Berger M.
No influence of ACE-inhibitors on cardio-selective beta-blockers on insulin sensitivity.
Diabetologia 36 (Suppl 1):A211, 1993
15. Heise T, Schubert H, Kimmerle R, Pußkailer M, Heinemann L, Bender R, Berger M.
Evaluation eines ambulanten Übergewichtigen-Therapieprogramms: Welche Faktoren beeinflussen bei dieser Hochrisikopopulation für Diabetes den Gewichtsverlust ?
Diabetes und Stoffwechsel 3:179, 1994
16. Starke AAR, Quintiliani S, Bender R, Heise T, Janicke I, Berger M.
Präzision des C-Peptid-Suppressions-Testes zum Ausschluss eines endogenen Hyperinsulinismus/Insulinoms.
Diabetes und Stoffwechsel 3:177, 1994
17. Heise T, Sawicki PT, Didjurgeit U, Mühlhauser I, Heinemann L, Berger M.
Beneficial effects of a hypertension and treatment programme in blind type I diabetic patients with overt nephropathy.
Patient Education and Counseling 23 (Suppl 1):S68, 1994
18. Heinemann L, Heise T, Wahl Ch, Ampudia J, Trautmann M, Berger M.
Pizza, Cola and Tiramisu: Can type I diabetic patients cover such a meal with the rapid acting insulin analogue LYSPRO?
Diabetologia 37 (Suppl 1):A78, 1994
19. Heise T, Bucher E, Heinemann L, Schinke U, Sawicki P, Berger M.
Waste of money in diabetes treatment.
Diabetologia 37 (Suppl 1):A27, 1994
20. Heise T, Kimmerle R, Heinemann L, Schubert H, Bender R, Pußkailer M, Berger M.
Weight reduction in an out-patient obesity clinic: Which factors are associated with success?
International Journal of Obesity 19 (Suppl 2):155, 1995
21. Heinemann L, Berger M, Böcker D, Christiansen JS, Essenpreis M, Gries FA, Heise T, Koschinsky T, Orskov H, Patterson MS, Schmelzeisen G.
Kontinuierliche nicht-invasive (Blut-)Zuckermessung im nahen Infrarot-Bereich.
Diabetes und Stoffwechsel 5 (Sonderheft):16, 1996
22. Heinemann L, Traut T, Heise T.
Wirkungsprofil von inhaliertem Insulin.
Diabetes und Stoffwechsel 5 (Sonderheft):78, 1996
23. Heinemann L, Kapitza C, Starke AAR, Heise T.
Wirkungsdauer des Insulinanalogons B28Asp im Vergleich zu kurzwirkendem Insulin.
Diabetes und Stoffwechsel 5 (Sonderheft):79, 1996
24. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT.
Keine Beeinflussung der Insulinsensitivität durch Enalapril und Nitrendipin bei Patienten mit essentieller Hypertonie.
Diabetes und Stoffwechsel 5 (Sonderheft):109, 1996

25. Heinemann L, Berger M, Böcker D, Christiansen JS, Essenpreis M, Gries FA, Heise T, Koschinsky T, Orskov H, Patterson MS, Schmelzeisen G.
Continuous non-invasive glucose monitoring in type I diabetic patients.
Diabetes 45 (Suppl 2):211A, 1996
26. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT.
No influence of enalapril and nitrendipine on insulin sensitivity in patients with essential hypertension.
Diabetes 45 (Suppl 2):186A, 1996
27. Heinemann L, Traut T, Heise T.
Time-action profile of inhaled insulin
Diabetes 45 (Suppl 2):212A, 1996
28. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT.
No influence of enalapril and nitrendipine on insulin sensitivity in patients with essential hypertension.
Kidney and Blood Pressure Research 20:122, 1996
29. Heinemann L, Kapitza C, Starke AAR, Heise T.
Duration of action of the insulin analogue B28Asp in comparison to regular insulin.
Diabetes 45 (Suppl 2):139A, 1996
30. Heinemann L, Traut T, Heise T.
Time-action profile of inhaled insulin.
Diabetologia 39 (Suppl 1):A25, 1996
31. Weyer C, Kapitza C, Starke AAR, Heise T, Heinemann L.
Duration of action of the insulin analogue B28Asp in comparison to regular insulin.
Diabetologia 39 (Suppl 1):A24, 1996
32. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT.
No influence of enalapril and nitrendipine on insulin sensitivity in patients with essential hypertension.
Diabetologia 39 (Suppl 1):A290, 1996
33. Heise T, Kimmerle R, Weyer C, Linkeschowa R, Bender R, Berger M, Spraul M.
Gewichtsreduktion in einer Übergewichtigen-Ambulanz: Welche Faktoren sind mit einer erfolgreichen Gewichtsabnahme assoziiert?
Aktuelle Ernährungs-Medizin 21:254, 1996
34. Rave K, Weyer C, Stiefelhagen O, Rauhaus M, Heise T, Heinemann L.
Comparison of the metabolic activity of the insulin analogue B28Asp with soluble insulin in U40 and U100 concentration.
Diabetologia 40 (Suppl 1):A354, 1997
35. Heinemann L, Weyer C, Osinga J, Heinrichs S, Heise T.
Variability of the metabolic effect of s.c. injected regular insulin and the rapid acting insulin analogue B28Asp.
Diabetologia 40 (Suppl 1):A10, 1997
36. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, Woodworth J, Heinemann L.
Time-action profiles of premixed formulations of insulin lispro and NPL-insulin.
Diabetologia 40 (Suppl 1):A354, 1997

37. Heise T, Heinemann L, Starke AAR.
Severe insulin resistance in a model of critical illness and parenteral nutrition.
Diabetologia 40 (Suppl 1):A290, 1997
38. Heinemann L, Stoffels M, Weyer C, Heise T.
Reliable blood glucose measurement with the APEC glucose analyzer.
Diabetologia 40 (Suppl 1):A356, 1997
39. Weyer C, Heise T, Heinemann L.
Premixed formulations of B28Asp and NPH-insulin: pharmacodynamic properties of a 30/70-stable mixture.
Diabetologia 40 (Suppl 1):A350, 1997
40. Meinhold J, Heise T, Heinemann L.
Hypoglycaemia detection by ECG recording: reproducible effects on T and R waves.
Diabetologia 40 (Suppl 1):A240, 1997
41. Magnusson K, Weyer Ch, Heise T, Heinemann L, Sawicki P.
Blunted vasodilatory effect of insulin in hypertensive obese subjects.
Diabetologia 40 (Suppl 1):A255, 1997
42. Heinemann L, Weyer Ch, Stiefelhagen O, Rauhaus M, Heise T.
Variabilität des metabolischen Effekts von s.c. injiziertem Normalinsulin und des rasch-wirkenden Insulinanalogons B28Asp.
Diabetes und Stoffwechsel 6 (Suppl 1):119, 1997
43. Meinhold J, Heise T, Heinemann L.
Hypoglykämieerkennung: Reproduzierbarkeit der Effekte einer Hypoglykämie auf das EKG.
Diabetes und Stoffwechsel 6 (Suppl 1):122, 1997
44. Rave K, Weyer Ch, Stiefelhagen O, Rauhaus M, Heise T, Heinemann L.
Vergleich der metabolischen Wirkung von U40- und U100-Normalinsulin und dem Insulin-Analogen B28Asp.
Diabetes und Stoffwechsel 6 (Suppl 1):58, 1997
45. Magnusson K, Weyer Ch, Heise T, Heinemann L, Sawicki P.
Verminderter vasodilatatorischer Effekt von Insulin in adipösen Patienten mit Hypertonie.
Diabetes und Stoffwechsel 6 (Suppl 1):147, 1997
46. Weyer Ch, Heise T, Heinemann L.
Pharmakodynamische Eigenschaften einer stabilen 30/70 Mischung mit dem rasch-wirkenden Insulin-Analogen B28Asp.
Diabetes und Stoffwechsel 6 (Suppl 1):120, 1997
47. Heise T, Weyer C, Serwas A, Osinga J, Heinrichs S, Roach P, Woodworth J, Heinemann L.
Wirkprofile von stabilen Mischungen von Insulin Lispro und NPL-Insulin.
Diabetes und Stoffwechsel 6 (Suppl 1):57, 1997
48. Heise T, Weyer C, Serwas A, Osinga J, Heinrichs S, Heinemann L.
Variability of the metabolic effect of s.c. injected regular insulin and the rapid acting insulin analogue B28Asp.
Diabetes 46 (Suppl 1):330A, 1997

49. Magnusson K, Weyer Ch, Heise T, Heinemann L, Sawicki P.
Blunted vasodilatory effect of insulin in hypertensive obese subjects.
Diabetes 46 (Suppl 1):350A, 1997
50. Weyer C, Heise T, Heinemann L.
Premixed formulations of B28Asp and NPH-insulin: pharmacodynamic properties of a 30/70-stable mixture.
Diabetes 46 (Suppl 1):152A, 1997
51. Heise T, Weyer C, Serwas A, Osinga J, Heinrichs S, Heinemann L.
Time-action profiles of premixed formulations of insulin lispro and NPL-insulin.
Diabetes 46 (Suppl 1):152A, 1997
52. Heise T, Kimmerle R, Weyer C, Linkeschowa R, Bender R, Berger M, Spraul M.
Predictors of successful weight reduction in an out-patient obesity-clinic.
International Journal of Obesity 21 (Suppl 2):S122, 1997
53. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT.
No influence of enalapril and nitrendipine on insulin sensitivity in patients with essential hypertension.
Kidney & Blood Pressure Research 20:122, 1997
54. Heise T, Rave K, Weyer C, Paul L, Gudat U, Roach P, Woodworth J, Heinemann L.
Premixed formulations of insulin lispro: activity profiles in type 1 diabetic patients.
Diabetes 47 (Suppl 1):A356, 1998
55. Heise T, Heinemann L, Stoffels M, Schaden U, Sawicki PT.
Effect of insulin on blood pressure in essential hypertension.
Diabetes 47 (Suppl 1):A356, 1998
56. Rave K, Heise T, Weyer C, Herrnberger J, Bender R, Hirschberger S, Heinemann L.
Intramuscular vs. subcutaneous injection of regular insulin and insulin lispro: comparison of the metabolic effects in healthy subjects.
Diabetes 47 (Suppl 1):A114, 1998
57. Rave K, Heise T, Sawicki PT, Heinemann L.
Measurement of Insulin Sensitivity: Influence of Potassium Supply during Euglycemic Glucose Clamp Studies in Healthy Volunteers.
Diabetes 47 (Suppl 1):A305, 1998
58. Rave K, Heise T, Weyer C, Herrnberger J, Bender R, Hirschberger S, Heinemann L.
Metabolische Effekte von i.m. vs. s.c. injiziertem Normalinsulin und Insulin Lispro.
Diabetes und Stoffwechsel 7 (Suppl 1):119, 1998
59. Heinemann L, Rave K, Weyer C, Paul L, Gudat U, Roach P, Woodworth J, Heise T.
Vorgefertigte Mischinsulinpräparate mit Insulin Lispro: Aktivitätsprofile in Patienten mit Diabetes mellitus Typ 1.
Diabetes und Stoffwechsel 7 (Suppl 1):116, 1998
60. Rave K, Heise T, Sawicki PT, Heinemann L.
Messung der Insulin-Sensitivität: Einfluss einer Kaliumsubstitution bei euglykämischen Glucose-Clamps.
Diabetes und Stoffwechsel 7 (Suppl 1):49, 1998

61. Heise T, Heinemann L, Stoffels M, Schaden U, Sawicki PT.
Wirkung von Insulin auf den Blutdruck bei Patienten mit essentieller Hypertonie.
Diabetes und Stoffwechsel 7 (Suppl 1):24, 1998
62. Kimmerle R, Heinemann L, Heise T, Weyer Ch, Hirschberger S, Berger M.
Einfluss einer kontinuierlichen Östrogen-Progestogen-Ersatztherapie mit
Estradiol-Norethisterone-Präparaten auf die Insulinsensitivität bei nicht-diabetischen
Frauen in der Menopause.
Diabetes und Stoffwechsel 7 (Suppl 1):50, 1998
63. Heise T, Rave K, Weyer C, Paul L, Gudat U, Roach P, Woodworth J, Heinemann L.
Premixed formulations of insulin lispro: activity profiles in type 1 diabetic patients.
Diabetologia 41 (Suppl 1):A242, 1998
64. Heise T, Heinemann L, Stoffels M, Schaden U, Sawicki PT.
Effect of insulin on blood pressure in essential hypertension.
Diabetologia 41 (Suppl 1):A175, 1998
65. Herrnberger J, Heise T, Rave K, Bender R, Hirschberger S, Heinemann L.
Intramuscular vs. subcutaneous injection of regular insulin and insulin lispro:
comparison of the metabolic effects in healthy subjects.
Diabetologia 41 (Suppl 1):A248, 1998
66. Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T, Heinemann L.
Time-action profile of the soluble, fatty acid acylated long-acting insulin analogue
NN304.
Diabetologia 41 (Suppl 1):A49, 1998
67. Heise T, Heinemann L, Stoffels M, Schaden U, Sawicki PT.
Effect of insulin on blood pressure in essential hypertension.
Journal of Hypertension 16 (Suppl 2):S199, 1998
68. Linkeschowa R, Rave K, Heise T, Hompesch B, Sedlak M, Heinemann L.
Wirkprofil des langwirkenden Insulin-Analogons HOE901.
Diabetes und Stoffwechsel 8 (Suppl 8):55, 1999
69. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T.
Intra-individuelle Variabilität der metabolischen Wirkung von inhaliertem Insulin mit
einem Absorptionsverstärker.
Diabetes und Stoffwechsel 8 (Suppl 8):32, 1999
70. Rave K, Heise T, Clauson P, Hirschberger S, Heinemann L.
Wirkung des β_3 -Adrenorezeptor Agonisten UL-TG 307 auf die Insulinsensitivität und
Insulinsekretion bei Typ-2 Diabetikern.
Diabetes und Stoffwechsel 8 (Suppl 8):71, 1999
71. Flesch S, Hompesch B, Linkeschowa R, Heise T, Clauson P, Hirschberger S,
Heinemann L.
Erhöhtes Hypoglykämie-Risiko durch Wechselwirkung zwischen ACE-Hemmern und
Sulfonylharnstoffen?
Diabetes und Stoffwechsel 8 (Suppl 8):22, 1999
72. Heise T, Hompesch B, Flesch S, Rave K, Linkeschowa R, Heinemann L.
Drug-interaction between enalapril and glibenclamide might lead to hypoglycemia.
Diabetes 48 (Suppl 1):A70, 1999

73. Heinemann L, Kraemer U, Kloetzer HM, Hermann M, for the Non-Invasive Task Force.
Non-invasive continuous glucose monitoring during physiological glucose changes in volunteers and diabetic patients.
Diabetes 48 (Suppl 1):A70, 1999
74. Rave K, Heise T, Clauson P, Hirschberger S.
Effects of the β_3 -adrenoceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in Type 2 diabetic patients.
Diabetes 48 (Suppl 1):A113, 1999
75. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T.
Intra-individual variability of the metabolic effect of inhaled insulin and enhancement of the effect by an absorption enhancer.
Diabetes 48 (Suppl 1):A108, 1999
76. Linkeschowa R, Rave K, Heise T, Hompesch B, Sedlak M, Heinemann L.
Time-action profile of the long-acting analogue HOE901.
Diabetes 48 (Suppl 1):A97, 1999
77. Heinemann L, Krämer U, Kloetzer HM, Hermann M, for the Non-Invasive Task Force.
Non-invasive continuous glucose monitoring during physiological glucose changes in volunteers and diabetic patients.
Diabetologia 42 (Suppl 1):A64, 1999
78. Linkeschowa R, Rave K, Heise T, Hompesch B, Sedlak M, Heinemann L.
Time-action profile of the long-acting analogue HOE901.
Diabetologia 42 (Suppl 1):A234, 1999
79. Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T, Heinemann L.
Intra-individual variability of the metabolic effect of inhaled insulin and enhancement of the effect by an absorption enhancer.
Diabetologia 42 (Suppl 1):A232, 1999
80. Flesch S, Hompesch B, Rave K, Linkeschowa R, Heinemann L, Heise T.
Drug-interaction between enalapril and glibenclamide might lead to hypoglycemia.
Diabetologia 42 (Suppl 1):A68, 1999
81. Rave K, Heise T, Clauson P, Hirschberger S, Heinemann L.
Lack of effects of the beta3-adrenoreceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in type 2 diabetic patients.
Diabetologia 42 (Suppl 1):A191, 1999
82. Heise T, Rave K, Bott S, Sha S, Willavize SA, Carroll RS, Gruber S, Lee JD, Heinemann L.
Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin.
Diabetes 49 (Suppl 1):A10, 2000
83. Rave K, Heise T, Pfützner A, Steiner SS, Heinemann L.
Results of a dose-response study with a new pulmonary insulin formulation and inhaler.
Diabetes 49 (Suppl 1):A75, 2000

84. Rave K, Sawicki P, Heise T, Heinemann L.
Pharmacodynamic properties of insulin in patients with and without diabetic nephropathy.
Diabetes 49 (Suppl 1):A76, 2000
85. Pfützner A, Heise T, Steiner SS, Heinemann L, Rave K.
Inhaled Technosphere/insulin shows a low variability in metabolic action in type 2 diabetic patients.
Diabetes 49 (Suppl 1):A121, 2000
86. Rave K, Heise T, Heinemann L.
Time-action profile of insulin glargine (HOE901) in Japanese volunteers.
Diabetes 49 (Suppl 1):A363, 2000
87. Steiner SS, Rave K, Heise T, Harzer O, Flacke F, Pfützner A, Heinemann L.
Bioavailability and Pharmacokinetic Properties of Inhaled Dry Powder Technosphere/Insulin.
Diabetes 49 (Suppl 1):A126, 2000
88. Rave K, Sawicki P, Heise T, Heinemann L.
Impact of diabetic nephropathy on pharmacodynamic properties of insulin lispro and regular insulin in patients with type 1 diabetes.
Experimental and Clinical Endocrinology & Diabetes 108 (Suppl 1):S30, 2000
89. Pfützner A, Rave K, Heise T, Steiner SS, Heinemann L.
Inhaled Technosphere/insulin results in low variability in metabolic action in type 2 diabetic patients.
Experimental and Clinical Endocrinology & Diabetes 108 (Suppl 1):S161, 2000
90. Rave K, Heise T, Pfützner A, Steiner SS, Heinemann L.
Assessment of dose-response characteristics for a new pulmonary insulin formulation and inhaler.
Experimental and Clinical Endocrinology & Diabetes 108 (Suppl 1):S161, 2000
91. Steiner SS, Rave K, Heise T, Harzer O, Flacke F, Pfützner A, Heinemann L.
Pharmacokinetic properties and bioavailability of inhaled dry powder Technosphere /insulin.
Experimental and Clinical Endocrinology & Diabetes 108 (Suppl 1):S161, 2000
92. Rave K, Heinemann L, Rosenkranz B, Heise T.
Time-action profile of insulin glargine (HOE901) in Japanese volunteers.
Experimental and Clinical Endocrinology & Diabetes 108 (Suppl 1):S161, 2000
93. Kapitza C, Heise T, Pfützner A, Steiner SS, Heinemann L, Rave K.
Dose-response characteristics for a new pulmonary insulin formulation and inhaler.
Diabetologia 43 (Suppl 1):A46, 2000
94. Bott S, Heinemann L, Rave K, Sha S, Willavize SA, Carroll RS, Gruber S, Lee, JD, Heise T.
Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin.
Diabetologia 43 (Suppl 1):A46, 2000

95. Heise T, Bott S, Rave K, Dressler A, Roßkamp R, Heinemann L.
No evidence for accumulation of HOE901 after multiple injections in type 1 diabetic patients.
Diabetologia 43 (Suppl 1):A196, 2000
96. Rave K, Sawicki PT, Heise T, Heinemann L.
Time-action profile of insulin lispro and regular insulin in patients with diabetic nephropathy.
Diabetologia 43 (Suppl 1):A197, 2000
97. Steiner SS, Rave K, Heise T, Harzer O, Flacke F, Pfützner A, Heinemann L.
TechnosphereTM/insulin bioavailability and pharmacokinetic properties in healthy volunteers.
Diabetologia 43 (Suppl 1):A201, 2000
98. Pfützner A, Rave K, Heise T, Steiner SS, Heinemann L.
Low variability in metabolic action in type 2 diabetic patients with inhaled TechnosphereTM/insulin.
Diabetologia 43 (Suppl 1):A202, 2000
99. Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L.
No evidence for accumulation of insulin glargine (HOE901): a multiple injection study in type 1 diabetic patients.
Diabetes und Stoffwechsel 10 (Suppl 1):52, 2001
100. Bott S, Heinemann L, Rave K, Sha S, Willavize SA, Carroll RS, Gruber S, Lee JD, Heise T.
Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin.
Diabetes und Stoffwechsel 10 (Suppl 1):67, 2001
101. Kapitza C, Nosek L, Leth G, Codony SG, Lindholm A, Heise T.
Biphasic Insulin Aspart provides good metabolic control even when injected postprandially.
Diabetes und Stoffwechsel 10 (Suppl 1):67, 2001
102. Kapitza C, Heise T, Heinemann L, Shapiro DA, Gopalakrishnan V, Fishman RS.
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
Diabetes 50 (Suppl 2):A118, 2001
103. Kapitza C, Nosek L, Lindholm A, Leth G, Codony SG, Heise T.
Biphasic Insulin Aspart provides good metabolic control even when injected postprandially.
Diabetes 50 (Suppl 2):A119, 2001
104. Pfützner A, Heinemann L, Heise T, Steiner SS, Flacke F, Forst T, Rave K.
Technosphere/Insulin.
Diabetes Technology & Therapeutics (Suppl 1), 2001
105. Edwards DA, Verma A, Heise T, Batycky RP
Efficacy, simplicity, and control of systemic protein delivery using large porous particle technology.
Journal of Aerosol Medicine 14:384, 2001

106. Heinemann L, Kapitza C, Heise T, Shapiro DA, Gopalakrishnan V, Fishman RS.
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
Diabetologia 44 (Suppl 1):A5, 2001
107. Pfützner A, Heinemann L, Steiner SS, Forst T, Heise T, Rave K.
Influence of small dose i.v., s.c. and pulmonary insulin treatment on prandial glucose control in patients with Type 2 diabetes.
Diabetologia 44 (Suppl 1):A212, 2001
108. Bott S, Shafagoi Y, Sawicki PT, Heise T.
Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients.
Diabetologia 44 (Suppl 1):A25, 2001
109. Hompesch M, Kapitza C, Scharling B, Thomsen LK, Heise T.
Intra-subject variability of pulmonary insulin via the AERx[®] insulin diabetes management system versus subcutaneous insulin.
Diabetologia 44 (Suppl 1):A212, 2001
110. Heise T, Scharling B, Bellaire S, Tusek C, Bott S.
Dose-response of pulmonary insulin with the AERx[®] insulin diabetes management system in healthy subjects.
Diabetologia 44 (Suppl 1):A212, 2001
111. Kapitza C, Nosek L, Lindholm A, Leth G, Codony SG, Heise T.
Postprandial dosing of the "lowmix" biphasic Insulin Aspart.
Diabetologia 44 (Suppl 1):A211, 2001
112. Perera A, Kapitza C, Nosek L, Heinemann L, Shapiro DA, Fishman RS, Heise T.
Reproducibility of inhaled and subcutaneous insulin in Type 2 diabetic patients.
Diabetologia 44 (Suppl 1):A212, 2001
113. Pfützner A, Heinemann L, Heise T, Steiner SS, Flacke F, Forst T, Rave K.
Technosphere/Insulin – eine rasch wirkende inhalative Formulierung zur prandialen Insulintherapie.
Diabetes und Stoffwechsel 10 (Suppl 2):8, 2001
114. Kapitza C, Hompesch M, Thomsen LK, Heise T.
Intra-Subject Variability of pulmonary Insulin via the Aerx[®] Insulin Diabetes Management System versus subcutaneous Insulin.
Diabetes und Stoffwechsel 11 (Suppl 1):6-5, 2002
115. Nosek L, Heinemann L, Kaiser M, Arnolds S, Heise T.
No Increase in the Duration of Action with Rising Doses of Insulin Aspart.
Diabetes und Stoffwechsel 12 (Suppl 1):V-109, 2003
116. Kapitza C, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T.
Oral Insulin: Proof of Concept in Type 2 Diabetic Patients.
Diabetes und Stoffwechsel 12 (Suppl 1):V-136, 2003
117. Hompesch M, Heise T, McGovern M, Cefali E, Buchwald A, Heinemann L, Kapitza C.
Time-Action Profile of a new Pulmonary Insulin Applied with a Metered-Dose Inhaler.
Diabetes und Stoffwechsel 12 (Suppl 1):V-137, 2003

118. Heise T, Heinemann L, Maggs D, McKay R, Cole L, Herrmann K, Wang Y, Burrell T, Weyer C.
Keine Beeinträchtigung der Hypoglykämie-Gegenregulation und -wahrnehmung durch das Amylin Analogon Pramlintide.
Diabetes und Stoffwechsel 12 (Suppl 1):P-90, 2003
119. Heise T, Tusek C, Bott S, Friberg HH, Heinemann L.
Keine Akkumulation der neuen Insulinmischungen Novomix 30 und Novomix 70.
Diabetes und Stoffwechsel 12 (Suppl 1):P-111, 2003
120. Bott S, Tusek C, Jacobsen LV, Kristensen A, Heise T.
Insulin Detemir reaches Steady-State after the First Day of Treatment and Shows a Peakless Time-Action Profile with Daily-Applications.
Diabetes und Stoffwechsel 12 (Suppl 1):P-113, 2003
121. Pfützner A, Heinemann L, Löbig M, Heise T, Steiner SS, Frost T.
Substitution der frühen Insulinsekretionsphase: Intaktes Proinsulin ist ein geeigneter Marker für die Erfassung der Sekretionsleistung der β -Zelle.
Diabetes und Stoffwechsel 12 (Suppl 1):P-106, 2003
122. Krones R, Heise T, Basir S, Klein C, Kaiser M, Sawicki P.
Wirkprofile von Humaninsulin und Insulin Aspart bei Patienten mit Diabetes mellitus Typ 2 in verschiedenen Altersgruppen.
Diabetes und Stoffwechsel 13 (Suppl 1):V-44, 2004
123. Heise T, Nosek L, Biilmann RØnn B, Endahl L, Heinemann L, Kapitza C, Draeger E.
Intra-individuelle Variabilität von Basalinsulinen: Vorteile von Insulin Detemir gegenüber NPH-Insulin und Insulin Glargin bei Patienten mit Typ-1-Diabetes.
Diabetes und Stoffwechsel 13 (Suppl 1):V-63, 2004
124. Kapitza C, Trautmann ME, Heise T, Heinemann L, Patterson B.
Daily Administration of LY307161 SR (GLP-1 Analog) Normalizes Blood Glucose in Type 2 Diabetes.
Diabetes 51 (Suppl 2):341-OR, 2002
125. Trautmann M. E, Kapitza C, Mace KF, Patterson B, Hompesch M, Heise T.
LY307161 SR, a Sustained Release Formulation of a GLP-1 Analog, Is Suitable for Once Daily Administration in Patients with Type 2 Diabetes.
Diabetes 51 (Suppl 2):545-P, 2002
126. Kapitza C, Hompesch M, Thomsen LK, Heise T.
Intra-Subject Variability of Pulmonary Insulin via the AERx® Insulin Diabetes Management System Versus Subcutaneous Insulin.
Diabetes 51 (Suppl 2):417-P, 2002
127. Trautmann ME, Kapitza C, Hompesch M, Heise T, Mace KF, Patterson B.
Once daily administration of LY307161 SR, a sustained release formulation of a GLP-1 Analogue, substantially reduces fasting and daytime glucose levels in patients with Type 2 diabetes.
Diabetologia 45 (Suppl 2):A43, 2002
128. Eising S, Zaß RP, Heise T, Koch HG, Harms E.
Impact of lipohypertrophy on metabolic control in paediatric patients with diabetes mellitus Type I.
Diabetologia 45 (Suppl 2):A283, 2002

129. Kapitza C, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T.
Oral Insulin: Proof of Concept in Type 2 Diabetic Patients
Diabetes 52 (Suppl 1):159-OR, 2003
130. Kapitza C, Heise T, McGovern M, Cefali E, Buchwald A, Heinemann L, Hompesch M.
Time-Action Profile of a New Pulmonary Insulin Applied with a Metered-Dose Inhaler.
Diabetes 52 (Suppl 1):449-P, 2003
131. Bott S, Tusek C, Jacobsen L, Kristensen A, Heise T.
Insulin Detemir Reaches Steady-State after the First Day of Treatment and Shows a
Peakless Time-Action Profile with Twice Daily-Applications.
Diabetes 52 (Suppl 1):480-P, 2003
132. Heise T, Tusek C, Bott S, Friberg H, Heinemann L.
Investigating the Drug Accumulation of Two Premixed Insulins.
Diabetes 52 (Suppl 1):519-P, 2003
133. Nosek L, Heinemann L, Kaiser M, Arnolds S, Heise T.
No Increase in the Duration of Action with Rising Doses of Insulin Aspart.
Diabetes 52 (Suppl 1):551-P, 2003
134. Heise T, Heinemann L, Maggs D, McKay R, Ruggles J, Wang Y, Burrell T, Weyer C.
Pramlintide Does Not Impair Symptomatic or Catecholaminergic Responses to
Hypoglycemia.
Diabetes 52 (Suppl 1):2007-PO, 2003
135. Steiner SS, Pfützner A, Heinemann L, Löbig M, Heise T, Forst T.
Intact but Not Total Proinsulin Predicts the Successful Imitation of First Phase Insulin
Release in Patients with Type 2 Diabetes.
Diabetes 52 (Suppl 1):2358-PO, 2003
136. Heise T, Nosek L, Draeger E, Biilmann Rønn B, Kapitza C, Heinemann L.
Lower within-subject variability of insulin Detemir compared to NPH insulin and insulin
Glargine in subjects with Type 1 diabetes.
Diabetologia 46 (Suppl 2):A6, 2003
137. Kapitza C, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T.
Oral insulin: proof of concept in Type 2 diabetic patients.
Diabetologia 46 (Suppl 2):A8, 2003
138. Caduff A, Buschor S, Dewarrat R, Schrepfer T, Nosek L, Heise T, Kapitza C,
Heinemann L.
Evaluation of a non-invasive, continuous glucose monitoring system in patients with
diabetes: results of a glucose clamp study with hypoglycaemic and hyperglycaemic
excursions.
Diabetologia 46 (Suppl 2):A45, 2003
139. Klein O, Nosek L, Plate J, Landvogt A, Heise T.
Determinations of the glycaemic index in diet products: how to overcome the
limitations of the classical approach.
Diabetologia 46 (Suppl 2):A263, 2003
140. Nosek L, Heinemann L, Kaiser M, Arnolds S, Heise T.
No increase in the duration of action with rising doses of insulin aspart.
Diabetologia 46 (Suppl 2):A268, 2003

141. Tusek C, Heinemann L, Bott S, Friberg HH, Heise T.
Investigating the drug accumulation of two premixed insulins.
Diabetologia 46 (Suppl 2):A269, 2003
142. Bott S, Tusek C, Jacobsen LV, Kristensen A, Heise T.
Insulin Detemir reaches steady-state after the first day of treatment and shows a peakless time-action profile with twice daily-applications.
Diabetologia 46 (Suppl 2):A271, 2003
143. Krones R, Heise T, Basir S, Klein C, Kaiser M, Sawicki PT.
Wirkprofile von Humaninsulin und Insulin Aspart bei Patienten mit Diabetes mellitus Typ 2 in verschiedenen Altersgruppen.
Diabetes und Stoffwechsel 13 (Suppl 1):21, 2004
144. Heise T, Nosek L, Biilmann Rønn B, Endahl L, Heinemann L, Kapitza C, Draeger E.
Intra-individuelle Variabilität von Basalinsulinen: Vorteile von Insulin Detemir gegenüber NPH-Insulin und Insulin Glargin bei Patienten mit Typ-1-Diabetes.
Diabetes und Stoffwechsel 13 (Suppl 1):30, 2004
145. Heise T, Tusek C, Stephan JA, Krasner A, Landschulz WH, Sha S, Becker RHA, Bott S.
Insulin Antibodies with Inhaled Insulin (Exubera®): No Evidence for Impact on Postprandial Glucose Control.
Diabetes 53 (Suppl 2):463-P, 2004
146. Becker RHA, Frick AD, Kapitza C, Heise T, Rave K.
Pharmacodynamics (PD) and Pharmacokinetics (PK) of Insulin Glulisine Compared with Insulin Lispro (IL) and Regular Human Insulin (RHI) in Patients with Type 2 Diabetes.
Diabetes 53 (Suppl 2):503-P, 2004
147. Krones R, Heise T, Basir S, Klein C, Kaiser M, Sawicki PT.
Time-action profiles of insulin aspart and human regular insulin in elderly and middle-aged subjects with Type 2 diabetes.
Diabetes 53 (Suppl 2):560-P, 2004
148. Nosek L, Becker RHA, Frick AD, Kapitza C, Heise T, Rave K.
Prandial Blood Glucose Control with Pre- and Post-Meal Insulin Glulisine Versus Regular Human Insulin.
Diabetes 53 (Suppl 2):588-P, 2004
149. Rave K, Nosek L, Posner J, Heise T, Van Hoogdalem E.
Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes: Is it Always 10 mmol/l?
Diabetes 53 (Suppl 2):2452-PO, 2004
150. Danne T, Rave K, Bittner C, Heise T, Frick AD, Becker RHA.
Pharmacokinetics and Safety of Insulin Glulisine in Children and Adolescents with Type 1 Diabetes.
Diabetes 53 (Suppl 2):2538-PO, 2004
151. Arbit E, Nosek L, Kapitza C, Beckett P, Gelfand R, Goldberg M, Heise T.
Oral insulin as first-line therapy in type 2 diabetes: a randomized-controlled pilot study.
Diabetologia 47 (Suppl 1):A5, 2004

152. Kapitza C, Becker RHA, Frick AD, Heise T, Rave K.
Pharmacodynamics and pharmacokinetics of insulin glulisine compared with insulin lispro and regular human insulin in patients with Type 2 diabetes.
Diabetologia 47 (Suppl 1):A265, 2004
153. Krones R, Heise T, Basir S, Klein C, Kaiser M, Sawicki PT.
Time-action profiles of insulin aspart and human regular insulin in elderly and middle-aged subjects with Type 2 diabetes.
Diabetologia 47 (Suppl 1):A266, 2004
154. Danne T, Rave K, Bittner C, Heise T, Frick AD, Becker RHA.
Pharmacokinetics and safety of insulin glulisine in children and adolescents with Type 1 diabetes.
Diabetologia 47 (Suppl 1):A297-298, 2004
155. Nosek L, Becker RHA, Frick AD, Kapitza C, Heise T, Rave K.
Prandial blood glucose with pre- and post-meal insulin glulisine versus regular human insulin.
Diabetologia 47 (Suppl 1):A300, 2004
156. Heinemann L, Rave K, Kronshage B, Nosek L, Heise T, Kapitza C, Ward K, Sass D, Essenspreis M, Völkel D, Lodwig V.
Continuous glucose monitoring for 5 days using a novel glucose-electrode in patients with Type 1 diabetes.
Diabetologia 47 (Suppl 1):A308, 2004
157. Heise T, Tusek C, Stephan JA, Krasner A, Landschulz WH, Sha S, Becker RHA, Bott S.
Postprandial glucose control unaffected by insulin antibodies associated with inhaled insulin.
Diabetologia 47 (Suppl 1):A311, 2004
158. Boss AH, Rave K, Heise T, Cheatham WW, Pfützner A.
Insulin bio-effect is limited by speed of absorption and elimination: similarities between an inhaled insulin formulation that mimics first-phase kinetics and i.v. insulin.
Diabetologia 47 (Suppl 1):A314, 2004
159. Cheatham WW, Rave K, Boss AH, Heise T.
Inhaled Technosphere/Insulin: Favourable time-action profile and low variability in comparison to subcutaneous human regular insulin.
Diabetologia 48 (Suppl 1):A30, 2005
160. Kapitza C, Nosek L, Arbit E, Beckett P, Gelfand R, Porter KM, Goldberg M, Heise T.
Reduction of postprandial blood glucose excursions by an optimised formulation of oral insulin.
Diabetologia 48 (Suppl 1):A31, 2005
161. Boss AH, Cheatham WW, Rave K, Heise T.
Markedly reduced postprandial glucose excursions through inhaled Technosphere/Insulin in comparison to sc injected regular insulin in subjects with type 2 diabetes
Diabetologia 48 (Suppl 1):A296, 2005

162. Hausmann M, Dellweg S, Heinemann L, Buchwald A, Heise T.
Add-on therapy with Kos inhaled insulin is as efficacious as add-on therapy with Lantus® in poorly controlled type 2 diabetic patients treated with sulfonylureas or metformin.
Diabetologia 48 (Suppl 1):A297, 2005
163. Heise T, Kapitza C, Jacobsen LV, Brondsted L, Heinemann L.
Pharmacokinetic and pharmacodynamic differences between premixed suspensions of insulin aspart: biphasic insulin aspart 30, 50 and 70.
Diabetologia 48 (Suppl 1):A301, 2005
164. Boss AH, Heise T, Rave K, Cheatham WW.
The Variability and Time-Action Profile of Inhaled Technosphere/Insulin Compares Favorably to That of Subcutaneous Human Regular Insulin.
Diabetes 54 (Suppl 1):358-OR, 2005
165. Hausmann M, Dellweg S, Heinemann L, Buchwald A, Heise T.
Add-On Therapy with Kos Inhaled Insulin Dosed Using a Metered Dose Inhaler Is as Efficacious as Add-On Therapy with Lantus® in Poorly controlled Type 2 Diabetic Patients Treated with Sulfonylureas or Metformin.
Diabetes 54 (Suppl 1):417-P, 2005
166. Heise T, Nosek L, Arbit E, Beckett P, Gelfand R, Porter KM, Goldberg M, Kapitza C.
Reduction of Postprandial Blood Glucose Excursions by an Optimized Formulation of Oral Insulin.
Diabetes 54 (Suppl 1):418-P, 2005
167. Troupin B, Elbroend B, Bernhard R, Heise T, Haahr H, Santiago O, Endahl L, Hompesch M.
Similar Pharmacodynamic and Pharmacokinetic Dose-Response Relationship of Insulin Detemir and NPH Insulin in African Americans, Hispanics or Latinos and Caucasians.
Diabetes 54 (Suppl 1):458-P, 2005
168. Becker RHA, Frick AD, Saoud JB, Nosek L, Heinemann L, Heise T, Rave K.
Variability in Concentration and Glucodynamic Profiles of Insulin Glargine in Healthy Volunteers.
Diabetes 54 (Suppl 1):586-P, 2005
169. Heise T, Nosek L, Heinemann L, Spitzer H, Niemoller E, Becker RHA, Frick AD, Schweitzer MA.
Consistent Fast Onset of Action and Absorption of Insulin Glulisine (GLU) in Lean to Obese Subjects.
Diabetes 54 (Suppl 1):588-P, 2005
170. Rave K, Dellweg S, Hovelmann U, Heise T, Dieck HT.
Impact of a Diet with Balantose™ on Insulin Resistance, Lipids and Body Weight: Results of a Randomized, Controlled Cross-Over Study in Obese Subjects with High Risk for Type 2 Diabetes.
Diabetes 54 (Suppl 1):1765-P, 2005
171. Heise T, Tusek C, Stephan JA, Krasner A, Lanschultz WH, Sha S, Becker RHA, Bott S.
Insulin-Antikörper, induziert durch inhalatives Insulin, beeinflussen die pharmakodynamischen und -kinetischen Eigenschaften von Insulin nicht.
Diabetes und Stoffwechselforschung 14 (Suppl):7, 2005

172. Rave K, Dellweg S, Hövelmann U, Heise T, Dieck TH.
Einfluss einer Diät mit BalantoseTM auf Insulinresistenz, Blutfette und Körpergewicht: Ergebnisse einer randomisierten, kontrollierten cross-over-Studie mit adipösen Personen mit hohem Risiko für Typ-2-Diabetes.
Diabetes und Stoffwechselforschung 14 (Suppl):58, 2005
173. Heise T, Kapitza C, Nosek L, Beckett P, Gelfand R, Goldberg M, Arbit E.
Oral insulin as first-line therapy in type-2-diabetes: A randomized-controlled pilot study.
Diabetes und Stoffwechselforschung 14 (Suppl):91, 2005
174. Heise T, Nosek L, Spitzer H, Heinemann L.
Glulisine: Schnellerer Wirkbeginn als Lispro bei schlanken bis stark übergewichtigen Patienten.
Diabetes und Stoffwechselforschung 14 (Suppl):92, 2005
175. Hausmann M, Dellweg S, Heinemann L, Buchwald A, Heise T.
Add-on therapy with Kos inhaled insulin dosed using a metered dose inhaler is as efficacious as add-on therapy with Lantus[®] in poorly controlled type-2-diabetic patients treated with sulfonylureas or metformin.
Diabetes und Stoffwechselforschung 14 (Suppl):92, 2005
176. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.
Insulin Detemir and Insulin Glargine: Similar Time-Action Profiles in Subjects with Type 2 Diabetes.
Diabetes 55 (Suppl 1):325-OR, 2006
177. Kapitza C, Heise T, Klein O, Granger C, Jallet K, Obach R, Ramis J, Prunyonosa J.
BIM51077, a Novel GLP-1 Analog, Achieves Sustained Improvement in Blood Glucose Control over 28 Days of Treatment.
Diabetes 55 (Suppl 1):500-P, 2006
178. Kapitza C, Heise T, Klein O, Granger C, Jallet K, Obach R, Ramis J, Prunyonosa J.
BIM51077, a Novel GLP-1 Analog, Showed Linear PK and Dose-Response Relationship over 7 Days of Treatment.
Diabetes 55 (Suppl 1):2019-PO, 2006
179. Heise T, Klein O, Lynge J, Endahl L, Damholt B, Nosek L.
Insulin detemir and insulin glargine: similar time-action profiles in subjects with type 2 diabetes.
Diabetologia 49 (Suppl 1):0146, 2006
180. Spitzer H, Heise T, Heinemann L, Nosek L, Frick AD, Becker RHA.
Insulin Glulisine: faster onset of absorption and action than insulin lispro in lean to obese subjects.
Diabetologia 49 (Suppl 1):0148, 2006
181. Roggen K, Rave K, Dellweg S, Heise T, tom Dieck H.
Improvement of insulin resistance after diet with a whole grain based dietary product: results of a randomised, controlled cross-over study in obese subjects with elevated fasting blood glucose.
Diabetologia 49 (Suppl 1):0845, 2006

182. Becker RHA, Frick AD, Nosek L, Heinemann L, Heise T, Rave K.
Variability in concentration and glucodynamic profiles of insulin glargine in healthy volunteers.
Diabetologia 49 (Suppl 1):1017, 2006
183. Nosek L, Becker RH, Frick AD, Kapitza C, Heise T, Rave K.
Prandiale Blutzucker Kontrolle mit vor und nach einer Mahlzeit injiziertem Insulinglulisin im Vergleich zu Normalinsulin.
Diabetologie und Stoffwechsel 1 (Suppl 1):182, 2006
184. Becker RH, Frick AD, Nosek L, Heinemann L, Heise T, Rave K.
Variabilität der pharmakokinetischen- und glukodynamischen Profile von Insulinglargin bei gesunden Probanden.
Diabetologie und Stoffwechsel 1 (Suppl 1):183, 2006
185. Kapitza C, Becker RH, Frick AD, Heise T, Rave K.
Pharmakodynamik und Pharmakokinetik von Insulinglulisin im Vergleich mit Insulinlispro und Normalinsulin bei Patienten mit Typ 2 Diabetes.
Diabetologie und Stoffwechsel 1 (Suppl 1):189, 2006
186. Kapitza C, Nosek L, Arbit E, Beckett P, Gelfand R, Porter KM, Goldberg M, Heise T.
Reduction of postprandial blood glucose excursions by an optimised formulation of oral insulin.
Diabetologie und Stoffwechsel 1 (Suppl 1):222, 2006
187. Heise T, Nosek L, Heinemann L, Spitzer H, Becker RHA, Frick AD.
The fast onset of action and absorption of insulin glulisine is maintained in healthy subjects across a broad range of body weights.
Diabetic Medicine 23 (Suppl 2):42, 2006
188. Heise T, Tiessen R, Huettner S, Ring A, Ritzhaupt A, Gräfe-Mody EU, Dugi KA.
The novel DPP-IV inhibitor BI 1356 significantly reduces postprandial glucose after an OGTT in people with type 2.
Diabetic Medicine 23 (Suppl 4):P833, 2006
189. Heise T, Klein O, Lynge J, Endahl L, Damholt B, Nosek L.
Insulin Detemir and insulin Glargine have similar pharmacodynamic properties in people with type 2 diabetes.
Diabetic Medicine 23 (Suppl 4):P910, 2006
190. Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.
Different premixed formulations of biphasic insulin aspart show clear differentiations in onset and duration of action.
Diabetic Medicine 24 (Suppl 1):44, 2006
191. Heise T, Tiessen R, Huettner S, Ring A, Ritzhaupt A, Gräfe-Mody EU, Dugi KA.
Treatment with BI 1356, a Novel and Potent DPP-IV Inhibitor, Significantly Reduces Glucose Excursions after an OGTT in Patients with Type 2 Diabetes.
Diabetes 56 (Suppl 1):0588-P, 2007
192. Arutchelvam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD.
Change in plasma glucose following exercise in type 1 diabetes: a comparison of three basal insulins.
Diabetologia 50 (Suppl 1):0043, 2007

193. Dugi KA, Heise T, Ring A, Gräfe-Mody EU, Ritzhaupt A, Huettner S.
BI 1356, a novel xanthine-based DPP-IV inhibitor, exhibits high potency with a wide therapeutic window and significantly reduces postprandial glucose excursions after an oGTT.
Diabetologia 50 (Suppl 1):0890, 2007
194. Kolb H, Schneider B, Heise T, Heinemann L, Lodwig V, Scherbaum W, Martin S.
Type 2 diabetes phenotype and progression is significantly different if diagnosed before versus after 65 years of age.
Diabetologia 50 (Suppl 1):0901, 2007
195. Eckers U, Heise T, Kanc K, Nielsen JN, Nosek L.
Clear differentiations in onset and duration of action are shown with different premixed ratios of biphasic insulin aspart (BIAsp).
Diabetologia 50 (Suppl 1):0963, 2007
196. Kolb H, Schneider B, Heinemann L, Heise T, Lodwig V, Scherbaum WA, Martin S.
Typ 2 Diabetes mit Diagnose vor dem 65. Lebensjahr ist signifikant anders als bei späterer Diagnose.
Diabetologie und Stoffwechsel 2 (Suppl 1):P172, 2007
197. Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.
Different premixed formulations of biphasic insulin aspart show clear differentiations in onset and duration of action.
Diabetic Medicine, 24 (Suppl 1):P50, 2007
198. Bonadonna RC, Kapitza C, Heise T, Avogaro A, Boldrin M, Grimsby J, Mulligan ME, Arbet-Engels C, Balena R.
Glucokinase activator RO4389620 improves beta cell function and plasma glucose fluxes in patients with type 2 diabetes.
Diabetologia 51 (Suppl 1):927, 2008
199. Heinemann L, Brugger A, Cook C, Eckers U, Hutchcraft A, Nosek L, Rave K, Troeger J, Valaitis P, Heise T.
Inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler.
Diabetologia 51 (Suppl 1):1012, 2008
200. Heinemann L, Nosek L, Rave K, Eckers U, Brugger A, Cook C, Hutchcraft A, Troeger J, Valaitis P, Heise T.
Inhaled Insulin: Safe and Efficacious Administration with a Commercially Available Dry Powder Inhaler.
Diabetes 57 (Suppl 1):2024-PO, 2008
201. Bonadonna RC, Kapitza C, Heise T, Avogaro A, Boldrin M, Grimsby J, Mulligan ME, Zhi J, Arbet-Engels C, Balena R.
Glucokinase activator RO4389620 improves beta cell function and plasma glucose fluxes in patients with type 2 diabetes.
Diabetes 57 (Suppl 1):332-OR, 2008
202. Hüttner S, Heise T, Gräfe-Mody EU, Ring A, Dugi KA.
BI 1356 (geplanter Handelsname ONDERO) ist ein neuer hochpotenter DPP-4-Inhibitor mit großer therapeutischer Breite.
Diabetologie und Stoffwechsel 3 (Suppl 1):S21, 2008

203. Arnolds S, Rave K, Hövelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin Glulisine Has a Faster Onset of Action Than Insulin Aspart. *Diabetes* 58 (Suppl1):528P, 2009
204. Jax T, Nosek L, Hövelmann U, Hermanski L, Kapitza C, Heise T, Heinemann L. Systematic Evaluation of the Influence of Hyperglycemia on Diastolic Myocardial Function. *Diabetes* 58 (Suppl1):2158-PO, 2009
205. Heise T, Mathieu C, Hey-Hadavi J, Strack T, Lawrence DE. Inhaled Insulin (Exubera®) Achieves Better A1c-Levels Than Insulin Glargine in Patients with Type 2 Diabetes mellitus Poorly Controlled by Oral Antidiabetic Agents. *Diabetes* 58 (Suppl1):2054-PO, 2009
206. Martin S, Herder C, Schloot NC, Heise T, Heinemann K, Kolb H, DIATOR Study Group. Preservation of residual beta cell function in newly diagnosed type 1 diabetes by treatment with atorvastatin: the DIATOR trial. *Diabetologia* 52 (Suppl 1):496, 2009
207. Hövelmann U, Arnolds S, Rave K, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action than insulin aspart. *Diabetologia* 52 (Suppl 1):890, 2009
208. Heise T, Heinemann L, Hövelmann U, Brauns, B, Nosek L, Haahr, H, Olsen KJ, Asimi T. NovoMix® 30 hat bei dreimal täglicher Gabe ein vergleichbares Wirkprofil wie eine Basis-Bolus Therapie mit den Analog-Insulinen Glargin und Glulisine. Konferenzband 37. Jahrestagung der ÖDG NOV19-21 2009, Salzburg, Austria, Poster Communication: Poster No 32, 2009
209. Heise T, Nosek L, Gable J, Lim G, Calentine C. ICU glucose monitoring measured in plasma using mid-infrared spectroscopy. *Critical Care* 2010, 14(Suppl 1):P580, 2010
210. Heise T, Tack CJ, Cuddihy BM, Davidson J, Gouet D, Liebl A, Bobillo ER, Mersebach H, Dykiel P, Jorde R. Once-daily use of a New Generation Ultra-long Acting Basal Insulin with a Bolus Boost in Insulin-Naïve Subjects with Type 2 Diabetes: Comparison with Insulin Glargine. *Diabetes* 59 (Suppl 1):34-OR, 2010
211. Zijlstra E, Hartlep M, O'Connell M, Heise T, Künnecke W. Accuracy of a Novel Continuous Glucose Monitoring System (CGMS) Using Intravenous (iv) Microdialysis. *Diabetes* 59 (Suppl 1):126-OR, 2010
212. Heise T, Nosek L, Gable J, Lim G, Calentine C. Intensive Care Unit (ICU) Glucose Monitoring Measured in Plasma using Mid-Infrared Spectroscopy. *Diabetes* 59 (Suppl 1):127-OR, 2010
213. Kolb H, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Martin S. Impact of Atorvastatin Treatment on Residual Beta Cell Function in Recent-Onset Type 1 Diabetes. *Diabetes* 59 (Suppl 1):396-PP, 2010

214. Heckermann S, Leszek N, Zijlstra E, Heise T.
Accuracy of a Continuous Glucose Monitoring System (CGMS): Still Room for Improvement.
Diabetes 59 (Suppl 1):489–P, 2010
215. Seman L, Macha S, Jones P, Marquart A, Port A, Pinnetti S, Heise T, Dugi KA.
Safety and Tolerability of BI 10773, a Sodium-Glucose Co-Transporter (SGLT-2) Inhibitor, Following 8-Days Treatment in Patients with Type 2 Diabetes.
Diabetes 59 (Suppl 1):571–P, 2010
216. Heise T, Nosek L, Flacke F, Krasner A, Pichotta P, Heinemann L, Steiner SS.
A Novel pH-Neutral Formulation of the Monomeric Insulin VIAject® Has a Faster Onset of Action Than Insulin Lispro.
Diabetes 59 (Suppl 1):622–P, 2010
217. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Huber K, Pinnetti S, Seman L, Woerle HJ.
BI 10773, a Sodium-Glucose Co-Transporter Inhibitor (SGLT-2), Is Safe and Efficacious Following 4-Week Treatment in Patients with Type 2 Diabetes.
Diabetes 59 (Suppl 1):629–P, 2010
218. Nosek L, Heise T, Flacke F, Krasner A, Pichotta P, Heinemann L, Steiner SS.
A Novel pH-Neutral Formulation of the Monomeric Insulin VIAject® Has a Faster Onset of Action Than Insulin Lispro.
Diabetologia 53 (Suppl 1):S6, 2010
219. Heckermann S, Leszek N, Zijlstra E, Heise T.
Accuracy of a Continuous Glucose Monitoring System (CGMS): Still Room for Improvement.
Diabetologia 53 (Suppl 1):48, 2010
220. Heise T, Nosek L, Gable J, Lim G, Calentine C.
Intensive Care Unit (ICU) Glucose Monitoring Measured in Plasma using Mid-Infrared Spectroscopy.
Diabetologia 53 (Suppl 1):231, 2010
221. Graefe-Mody U, Friedrich C, Port A, Ring A, Heise T, Halabi A, Woerle HJ.
Linagliptin, a novel DPP-4 inhibitor: No need for dose adjustment in patients with renal impairment.
Diabetologia 53 (Suppl 1):822, 2010
222. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, Haahr H.
Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions.
Diabetologia 53 (Suppl 1):971, 2010
223. R Cuddihy R, Tack CJ, Heise T, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R.
Once-daily use of a new generation ultra-long acting basal insulin with a bolus boost in insulin-naive people with type 2 diabetes: comparison with insulin glargine
Diabetologia 53 (Suppl 1):975, 2010

224. Heise T, Tack CJ, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R.
A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes. A randomized, controlled trial.
Diabetes Care 34:669-674, 2011